Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ambroxol SCHEMBL28472066 | 1.00 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL7855003 | 1.00 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL423712 | 1.00 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL18702 | 1.00 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL99455 | 0.99 | CYP3A4 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL6601413 | 0.99 | CYP3A4 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL1648757 | 0.97 | CYP2D6 (0.94) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL11533052 | 0.93 | CYP2D6 (0.87) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| SCHEMBL24446418 | 0.92 | CYP2D6 (0.84) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| SCHEMBL22927201 | 0.92 | CYP2D6 (0.84) | CYP2D6SLC6A4KCNH2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12619005-B2 | Optical film with improved optical properties, display apparatus comprising same, and manufacturing method therefor | KOLON INDUSTRIES, INC. (KR) | 2026-05-05 | — | — | US | claimed |
| EP-4178606-B1 | THERAPEUTIC HYBRID MICRONEEDLE PATCH FOR THE DELIVERY OF INSULIN AND GLUCAGON | THE REGENTS OF UNIV OF CALIFORNIA (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4304346-B1 | AN AQUAFARMING TANK FOR GROWING WATER-LIVING SPECIES AND A METHOD OF CONSTRUCTING THE AQUAFARMING TANK | FUERSTENBERG AMFI LTD (LV) | 2025-04-30 | — | — | EP | claimed |
| CN-119770419-A | Modified recombinant III type collagen hydrogel loaded with houttuynia cordata vesicles and application thereof | 常州大学 | 2025-04-08 | — | — | CN | claimed |
| US-20240272140-A1 | DIAGNOSIS AND TREATMENT OF FUSARIOSIS AND SCEDOSPORIOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2024-08-15 | — | — | US | claimed |
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE LLC (US) | 2024-02-22 | — | — | US | claimed |
| EP-4304346-A1 | AN AQUAFARMING TANK FOR GROWING WATER-LIVING SPECIES AND A METHOD OF CONSTRUCTING THE AQUAFARMING TANK | Amfitop Aqua Farming Ltd. (LV) | 2024-01-17 | — | — | EP | claimed |
| US-20230375750-A1 | OPTICAL FILM WITH IMPROVED OPTICAL PROPERTIES, DISPLAY APPARATUS COMPRISING SAME, AND MANUFACTURING METHOD THEREFOR | KOLON INDUSTRIES, INC. (KR) | 2023-11-23 | — | — | US | claimed |
| US-20230240981-A1 | THERAPEUTIC HYBRID MICRONEEDLE PATCH FOR THE DELIVERY OF INSULIN AND GLUCAGON | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-03 | — | — | US | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| EP-4178606-A1 | THERAPEUTIC HYBRID MICRONEEDLE PATCH FOR THE DELIVERY OF INSULIN AND GLUCAGON | The Regents of University of California (US) | 2023-05-17 | — | — | EP | claimed |
| CN-115811985-A | Therapeutic hybrid microneedle patch for delivery of insulin and glucagon | 加利福尼亚大学董事会 | 2023-03-17 | — | — | CN | claimed |
| CN-115707459-A | Synergistic composition of drug-resistant tumor treatment drugs | 复旦大学 | 2023-02-21 | — | — | CN | claimed |
| WO-2022263321-A1 | AN AQUAFARMING TANK FOR GROWING WATER-LIVING SPECIES AND A METHOD OF CONSTRUCTING THE AQUAFARMING TANK | AMFITOP SOLID SURFACE PRODUCTS (LV) | 2022-12-22 | — | — | WO | claimed |
| WO-2022224118-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE, LLC (US) | 2022-10-27 | — | — | WO | claimed |
| US-20220331408-A1 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | GENETHON (FR) | 2022-10-20 | — | — | US | claimed |
| EP-3996696-A1 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | Genethon (FR) | 2022-05-18 | — | — | EP | claimed |
| CN-122055820-A | Formulations comprising 3-amino-3-methyl-2-butanol and their use in electrical and electronic applications | 安达伟胜股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2022021769-A1 | AMBROXOL HYDROCHLORIDE ORAL SPRAY SOLUTION AND PREPARATION METHOD THEREFOR | 德国吉麦医疗技术有限公司 | 2022-02-03 | — | — | WO | disclosed |
| WO-2022021769-A1 | AMBROXOL HYDROCHLORIDE ORAL SPRAY SOLUTION AND PREPARATION METHOD THEREFOR | 德国吉麦医疗技术有限公司 | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12619005-B2 | Optical film with improved optical properties, display apparatus comprising same, and manufacturing method therefor | SETDB1, TRAFD1, RFC5 | CYP2D6 4636/4885SLC6A4 3304/4885KCNH2 4112/4885 |
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | BAG3, BAG2, PHB1 | CYP2D6 2282/4885SLC6A4 1391/4885KCNH2 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.